According to TipRanks’ statistics, Martin Shkreli has a 46% transaction rate (profitable transactions) and an average return of 61.6% per transaction.
Chipotle Mexican Grill, Inc. (NYSE:CMG) is up almost 5% in early morning trading, despite analyst downgrades and bearish sentiment. The downgrades come after Friday’s news that the E.coli outbreak had spread from the its stores in the Pacific Northwest to other states. In total, 45 people have been affected by the bacteria with 43 stating they ate at a Chipotle a week before they noticed symptoms. The company has been in hot water since October, when the E Coli news was first linked to the company, forcing it to close 43 of its stores. Analyst Nicole Miller Regan from Piper Jaffray weighed in on the stock, reiterating an overweight rating and a price target of $737. She believes that other companies, with similar history of food borne illnesses, suffered from declining revenues and Chipotle is not immune to these affects. Analysts from Sterne Agee and BofA/Merrill lynch also expressed bearish sentiments and downgraded the stock.
According to TipRanks’ statistics, out of the 16 analyst who have rated CMG in the last 3 months, 8 gave a Buy rating, 1 gave a Sell rating, and 1 remains on the sidelines. The average 12-month price target for the stock is $726.14, marking a 34% upside from where shares last closed.
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares rose 5% this morning, adding to their 28% rise following Friday’s news that the FDA released a hostile review of competitor BioMartin Pharmaceuticals DMD drug drisapersen. The report highlighted safety concerns about the drug, stating that some patients “experience severe toxicity across many organ systems while using the drug.” Sarepeta is also currently developing a DMD drug, directly competing with BioMartin over which company can bring the treatment to market. The FDA is set to make an approval decision for BioMartin later this week. Although Serepta’s clinical trials were not also flawed, one of the company’s drugs will gain approval due to the high demand for DMD treatments.
According to TipRanks’ statistics, out of the 11 analysts who have rated SRPT in the last 3 months, 9 have a Buy rating, 1 gave a Sell rating, and 1 remains on the sidelines. The average 12-month price target for the stock is $35.55, marking a 6% upside from where shares last closed.